Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany

Table 3

Treatment intensity in the 1st-line treatment of patients with advanced or metastatic esophagogastric adenocarcinoma () documented in Therapiemonitor 2006–2013. Indicated is the percentage of patients receiving the respective treatment in the indicated years and/or quarters.

	2008 (%)	2009 (%)	2010 (%)	2011 (%)	2012 (%)	2013 (%)
Monochemotherapy	11.8	6.4	6.1	7.3	7.7	10.1
Chemotherapy doublet	57.7	46.6	33.7	29.0	32.9	35.9
Chemotherapy triplet	30.5	47.0	58.4	60.2	54.2	49.3
Chemotherapy > triplet	—	—	1.9	3.5	5.2	6.7

Note. Folinic acid is not considered an active drug and is consequently not included in this analysis.
In 2013 folinic acid was asked as a separate drug, but see Note above.